Phase II Study of Combination of Hyper-CVAD with Ponatinib in Frontline Therapy of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph-positive ALL)

Artigo Revisado por pares

Phase II Study of Combination of Hyper-CVAD with Ponatinib in Frontline Therapy of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph-positive ALL)

2015; Elsevier BV; Volume: 15; Linguagem: Inglês

10.1016/j.clml.2015.07.013

ISSN

2152-2650

Autores

Koji Sasaki, Susan O’Brien, Farhad Ravandi, Deborah A. Thomas, Haim G. Moore, Jorge E. Cortés, Naveen Pemmaraju, Musa Yılmaz, Tapan M. Kadia, Rebecca Garris, Guillermo Garcia‐Manero, Vicky Jeanis, Gautam Borthakur, William G. Wierda, Alessandra Ferrajoli, Hagop M. Kantarjian, Elias Jabbour,

Tópico(s)

Chronic Lymphocytic Leukemia Research

Resumo

Ponatinib is a more potent BCR-ABL inhibitor, and covers the T315I clones. The combinations of chemotherapy and ponatinib may be associated with better response rates and higher likelihood of eradication of minimal residual disease (MRD) in patients with Ph-positive ALL.

Ver no editor

Altmetric

PlumX

Entrar

Lembrar minha senha

Receber meu e-mail de confirmação

Phase II Study of Combination of Hyper-CVAD with Ponatinib in Frontline Therapy of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph-positive ALL)